PSC
Patient Square Capital Portfolio holdings
AUM
$277M
This Quarter Return
+1.86%
1 Year Return
+6.76%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$267M
AUM Growth
+$267M
(-0.76%)
Cap. Flow
-$10.5M
Cap. Flow
% of AUM
-3.92%
Top 10 Holdings %
Top 10 Hldgs %
89.8%
Holding
20
New
9
Increased
9
Reduced
2
Closed
–
Top Buys
| 1 |
Insmed
INSM
|
$9.35M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.01M |
| 3 |
Geron
GERN
|
$4.68M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$4M |
| 5 |
Disc Medicine
IRON
|
$3.58M |
Top Sells
| 1 |
Liquidia Corp
LQDA
|
$62.6M |
| 2 |
Pharvaris
PHVS
|
$666K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$8.15B
| $148M | 55.22% |
12,480,000
+251,535
| +2% | +$2.98M |
|
|
2
Liquidia Corp
LQDA
$2.38B
| $21.9M | 8.18% |
1,860,371
-5,322,161
| -74% | -$62.6M |
|
|
3
Insmed
INSM
$28.8B
| $21.2M | 7.93% |
307,167
+135,463
| +79% | +$9.35M |
|
4
Cullinan Oncology
CGEM
$445M
| $10.7M | 4% |
878,897
+54,192
| +7% | +$660K |
|
5
EyePoint Pharmaceuticals
EYPT
$797M
| $10.5M | 3.93% |
1,410,331
+48,352
| +4% | +$360K |
|
6
Nurix Therapeutics
NRIX
$714M
| $8.41M | 3.14% |
446,296
+120,507
| +37% | +$2.27M |
|
|
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.01M | 2.25% |
+71,990
| New | +$6.01M |
|
8
Enliven Therapeutics
ELVN
$1.2B
| $5.04M | 1.89% |
224,038
+133,466
| +147% | +$3M |
|
|
9
Geron
GERN
$893M
| $4.68M | 1.75% |
+1,321,268
| New | +$4.68M |
|
10
Ocular Therapeutix
OCUL
$2.12B
| $4.02M | 1.5% |
470,919
+235,421
| +100% | +$2.01M |
|
|
11
Agios Pharmaceuticals
AGIO
$2.19B
| $4M | 1.5% |
+121,732
| New | +$4M |
|
|
12
Pharvaris
PHVS
$1.39B
| $3.98M | 1.49% |
207,603
-34,738
| -14% | -$666K |
|
|
13
Disc Medicine
IRON
$2.07B
| $3.58M | 1.34% |
+56,400
| New | +$3.58M |
|
|
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
| $3.37M | 1.26% |
+93,137
| New | +$3.37M |
|
15
Allogene Therapeutics
ALLO
$251M
| $3.17M | 1.19% |
+1,489,909
| New | +$3.17M |
|
16
Mirum Pharmaceuticals
MIRM
$3.71B
| $2.68M | 1% |
+64,900
| New | +$2.68M |
|
17
Intellia Therapeutics
NTLA
$1.22B
| $2.52M | 0.94% |
215,981
+87,412
| +68% | +$1.02M |
|
18
Arvinas
ARVN
$568M
| $1.66M | 0.62% |
+86,627
| New | +$1.66M |
|
19
Scholar Rock
SRRK
$3.14B
| $1.38M | 0.52% |
+32,000
| New | +$1.38M |
|
20
Astria Therapeutics
ATXS
$349M
| $939K | 0.35% |
105,057
+65,635
| +166% | +$587K |
|